We are live on ! Find out more
CPRX

Catalyst Pharmaceutical
CPRX

Delisted

CPRX was delisted on the 14th of July, 2026.

Back to rankings

229 hedge funds and large institutions have $1.09B invested in Catalyst Pharmaceutical in 2022 Q3 according to their latest regulatory filings, with 66 funds opening new positions, 66 increasing their positions, 67 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

175% more first-time investments, than exits

New positions opened: 66 | Existing positions closed: 24

150% more funds holding in top 10

Funds holding in top 10: 2 → 5 (+3)

138% more capital invested

Capital invested by funds: $459M → $1.09B (+$634M)

25% more call options, than puts

Call options by funds: $2.9M | Put options by funds: $2.31M

21% more funds holding

Funds holding: 189 → 229 (+40)

9.36% more ownership

Funds ownership: 73.45% → 82.81% (+9.4%)

1% less repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 67

Holders
229
Holders Change
+40
Holders Change %
+21.16%
% of All Funds
3.94%
Holding in Top 10
5
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+150%
% of All Funds
0.09%
New
66
Increased
66
Reduced
67
Closed
24
Calls
$2.9M
Puts
$2.31M
Net Calls
+$583K
Net Calls Change
+$9K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$98.6M
2
DM
Deerfield Management
New York
+$58M
3
State Street
State Street
Massachusetts
+$25.1M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$15.1M
5
Two Sigma Investments
Two Sigma Investments
New York
+$15.1M

Top Sellers

Rank Fund Capital Flow
1
RA
Royce & Associates
New York
-$17.1M
2
Millennium Management
Millennium Management
New York
-$15.2M
3
Goldman Sachs
Goldman Sachs
New York
-$14.1M
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$10.1M
5
Allianz Asset Management
Allianz Asset Management
Germany
-$7.68M
Name Holding Trade Value Shares
Change 		Change in
Stake
SAM
101
Shell Asset Management
Netherlands
$793K -$192K -16,198 -21%
Wellington Management Group
102
Wellington Management Group
Massachusetts
$792K -$1.29M -108,696 -64%
NYLIM
103
New York Life Investment Management
New York
$784K +$57.3K +4,834 +9%
VRS
104
Virginia Retirement Systems
Virginia
$767K +$709K +59,800 New
AssetMark Inc
105
AssetMark Inc
California
$759K +$701K +59,132 New
VOYA Investment Management
106
VOYA Investment Management
Georgia
$756K +$254K +21,436 +57%
AIM
107
Aigen Investment Management
New York
$744K +$687K +57,986 New
MAM
108
Martingale Asset Management
Massachusetts
$725K -$536K -45,226 -44%
LS
109
Livforsakringsbolaget Skandia
Sweden
$713K – – –
Mackenzie Financial
110
Mackenzie Financial
Ontario, Canada
$712K -$5.64K -476 -0.9%
Robeco Institutional Asset Management
111
Robeco Institutional Asset Management
Netherlands
$704K +$651K +54,939 New
MIM
112
MetLife Investment Management
New Jersey
$681K – – –
State of Tennessee, Department of Treasury
113
State of Tennessee, Department of Treasury
Tennessee
$681K +$630K +53,137 New
AIG
114
American International Group
New York
$672K +$89.5K +7,548 +17%
FHB
115
First Hawaiian Bank
Hawaii
$659K – – –
GAM
116
Gotham Asset Management
New York
$644K +$595K +50,175 New
YMRC
117
Yorktown Management & Research Company
Virginia
$642K – – –
Wells Fargo
118
Wells Fargo
California
$640K +$432K +36,411 +271%
AR
119
Advisory Research
Illinois
$623K +$575K +48,531 New
Royal Bank of Canada
120
Royal Bank of Canada
Ontario, Canada
$622K +$72.9K +6,155 +15%
JF
121
Jump Financial
Illinois
$609K -$408K -34,401 -42%
PP
122
PDT Partners
New York
$602K +$91.8K +7,748 +20%
JAM
123
Jupiter Asset Management
United Kingdom
$595K +$186K +15,679 +51%
AB
124
Amalgamated Bank
New York
$592K +$367K +30,960 +204%
LSERS
125
Louisiana State Employees Retirement System
Louisiana
$580K +$536K +45,200 New
3 4
5
6 7

CPRX Hedge Fund Activity: Q3 2022 in Review

229 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q3 2022, worth a combined $1.09B — up 138% from $459M a quarter earlier.

Buyers outnumbered sellers: 66 funds opened new CPRX positions and 24 closed out — a net gain of 42 holders — while 66 added to existing stakes and 67 trimmed.

The largest buyer was BlackRock, adding an estimated $98.6M. The largest seller was Royce & Associates, cutting an estimated $17.1M.

  • 229 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q3 2022, up from 189 in Q2 2022.
  • Funds reported $1.09B of Catalyst Pharmaceutical stock for Q3 2022, up 138% quarter-over-quarter.
  • 66 funds opened new Catalyst Pharmaceutical positions in Q3 2022 and 24 closed out, a net change of +42 holders.
  • The largest Catalyst Pharmaceutical buyer in Q3 2022 was BlackRock, an estimated $98.6M added.
  • The largest Catalyst Pharmaceutical seller in Q3 2022 was Royce & Associates, an estimated $17.1M sold.

Based on aggregated 13F filings for Q3 2022.